News

Video

CURE's Top Stories: February 2020

Here are the top five CURE® stories for February 2020.

Here are the top five CURE® stories for February 2020.

5. “I Never Met Frederic Mohs”

In this reader-submitted story, a skin cancer survivor shares his experience with squamous and basal cell carcinoma — and the healthy-tissue-sparing surgery that removed those cancerous cells and has him back to living life to the fullest.

4. Understanding Prevention For Hereditary Cancer

In honor of National Cancer Prevention Month, we take an in-depth look at how knowledge is power when it comes to hereditary cancers, in this piece.

3. Just Remember Not to Stop

Here, a cancer survivor laments not getting more done until she realizes that she just moves slower, and that's OK. As long as you don't stop.

2. New Blood Test Could Detect Cancer Cells

In this story, we look at a new study that supports the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, potentially giving patients a non-invasive screening and testing method.

1. Finding Purpose After Five Different Cancers

In this episode of the “CURE Talks Cancer” podcast, we spoke with Lainie Jones, who found her purpose in helping others after being diagnosed with five separate primary cancers before the age of 35 because of Li-Fraumeni syndrome, a rare genetic condition that predisposes her to develop the disease.

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.